651 research outputs found
Does influenza vaccination improve pregnancy outcome? Methodological issues and research needs
AbstractEvidence that influenza vaccination during pregnancy is safe and effective at preventing influenza disease in women and their children through the first months of life is increasing. Several reports of reduced risk of adverse outcomes associated with influenza vaccination have generated interest in its potential for improving pregnancy outcome. Gavi, the Vaccine Alliance, estimates maternal influenza immunization programs in low-income countries would have a relatively modest impact on mortality compared to other new or under-utilized vaccines, however the impact would be substantially greater if reported vaccine effects on improved pregnancy outcomes were accurate. Here, we examine the available evidence and methodological issues bearing on the relationship between influenza vaccination and pregnancy outcome, particularly preterm birth and fetal growth restriction, and summarize research needs. Evidence for absence of harm associated with vaccination at a point in time is not symmetric with evidence of benefit, given the scenario in which vaccination reduces risk of influenza disease and, in turn, risk of adverse pregnancy outcome. The empirical evidence for vaccination preventing influenza in pregnant women is strong, but the evidence that influenza itself causes adverse pregnancy outcomes is inconsistent and limited in quality. Studies of vaccination and pregnancy outcome have produced mixed evidence of potential benefit but are limited in terms of influenza disease assessment and control of confounding, and their analytic methods often fail to fully address the longitudinal nature of pregnancy and influenza prevalence. We recommend making full use of results of randomized trials, re-analysis of existing observational studies to account for confounding and time-related factors, and quantitative assessment of the potential benefits of vaccination in improving pregnancy outcome, all of which should be informed by the collective engagement of experts in influenza, vaccines, and perinatal health
Pregnancy as a risk factor for severe influenza infection: an individual participant data meta-analysis
BACKGROUND: WHO identifies pregnant women to be at increased risk for severe outcomes from influenza virus
infections and recommends that they be prioritized for influenza vaccination. The evidence supporting this,
however, is inconsistent. Ecologic studies in particular suggest more severe outcomes from influenza infection
during pregnancy than studies based on individual patient data. Individual studies however may be underpowered
and, as reported in a previous systematic review, confounding factors could not be adjusted for. We therefore
conducted an individual participant data meta-analysis to assess the risk for severe outcomes of influenza infection
in pregnant women while adjusting for other prognostic factors.
METHODS: We contacted authors of studies included in a recently published systematic review. We pooled the
individual participant data of women of reproductive age and laboratory confirmation of influenza virus infection.
We used a generalized linear mixed model and reported odds ratios (OR) and 95% confidence intervals (CI).
RESULTS: A total of 33 datasets with data on 186,656 individuals were available, including 36,498 eligible women of
reproductive age and known pregnancy status. In the multivariable model, pregnancy was associated with a 7
times higher risk of hospital admission (OR 6.80, 95%CI 6.02–7.68), among patients receiving medical care as in- or
outpatients, pregnancy was associated with a lower risk of admission to intensive care units (ICU; OR 0.57, 95%CI
0.48–0.69), and was not significantly associated with death (OR 1.00, 95%CI 0.75–1.34).
CONCLUSIONS: Our study found a higher risk of influenza associated hospitalization among pregnant women as
compared to non-pregnant women. We did not find a higher mortality rate or higher likelihood of ICU admission
among pregnant women who sought medical care. However, this study did not address whether a true
community based cohort of pregnant women is at higher risk of influenza associated complications
Pregnancy as a risk factor for severe influenza infection: an individual participant data meta-analysis
Background: WHO identifies pregnant women to be at increased risk for severe outcomes from influenza virus
infections and recommends that they be prioritized for influenza vaccination. The evidence supporting this,
however, is inconsistent. Ecologic studies in particular suggest more severe outcomes from influenza infection
during pregnancy than studies based on individual patient data. Individual studies however may be underpowered
and, as reported in a previous systematic review, confounding factors could not be adjusted for. We therefore
conducted an individual participant data meta-analysis to assess the risk for severe outcomes of influenza infection
in pregnant women while adjusting for other prognostic factors.
Methods: We contacted authors of studies included in a recently published systematic review. We pooled the
individual participant data of women of reproductive age and laboratory confirmation of influenza virus infection.
We used a generalized linear mixed model and reported odds ratios (OR) and 95% confidence intervals (CI).
Results: A total of 33 datasets with data on 186,656 individuals were available, including 36,498 eligible women of
reproductive age and known pregnancy status. In the multivariable model, pregnancy was associated with a 7
times higher risk of hospital admission (OR 6.80, 95%CI 6.02–7.68), among patients receiving medical care as in- or
outpatients, pregnancy was associated with a lower risk of admission to intensive care units (ICU; OR 0.57, 95%CI
0.48–0.69), and was not significantly associated with death (OR 1.00, 95%CI 0.75–1.34).
Conclusions: Our study found a higher risk of influenza associated hospitalization among pregnant women as
compared to non-pregnant women. We did not find a higher mortality rate or higher likelihood of ICU admission
among pregnant women who sought medical care. However, this study did not address whether a true
community based cohort of pregnant women is at higher risk of influenza associated complications
Recommended from our members
The Prevalence and Clinical Implications of Comorbid Back Pain in Shoulder Instability: A Multicenter Orthopaedic Outcomes Network (MOON) Shoulder Instability Cohort Study.
Background:Understanding predictors of pain is critical, as recent literature shows that comorbid back pain is an independent risk factor for worse functional and patient-reported outcomes (PROs) as well as increased opioid dependence after total joint arthroplasty. Purpose/Hypothesis:The purpose of this study was to evaluate whether comorbid back pain would be predictive of pain or self-reported instability symptoms at the time of stabilization surgery. We hypothesized that comorbid back pain will correlate with increased pain at the time of surgery as well as with worse scores on shoulder-related PRO measures. Study Design:Cross-sectional study; Level of evidence, 3. Methods:As part of the Multicenter Orthopaedic Outcomes Network (MOON) Shoulder Instability cohort, patients consented to participate in pre- and intraoperative data collection. Demographic characteristics, injury history, preoperative PRO scores, and radiologic and intraoperative findings were recorded for patients undergoing surgical shoulder stabilization. Patients were also asked, whether they had any back pain. Results:The study cohort consisted of 1001 patients (81% male; mean age, 24.1 years). Patients with comorbid back pain (158 patients; 15.8%) were significantly older (28.1 vs 23.4 years; P < .001) and were more likely to be female (25.3% vs 17.4%; P = .02) but did not differ in terms of either preoperative imaging or intraoperative findings. Patients with self-reported back pain had significantly worse preoperative pain and shoulder-related PRO scores (American Shoulder and Elbow Surgeons score, Western Ontario Shoulder Instability Index) (P < .001), more frequent depression (22.2% vs 8.3%; P < .001), poorer mental health status (worse scores for the RAND 36-Item Health Survey Mental Component Score, Iowa Quick Screen, and Personality Assessment Screener) (P < .01), and worse preoperative expectations (P < .01). Conclusion:Despite having similar physical findings, patients with comorbid back pain had more severe preoperative pain and self-reported symptoms of instability as well as more frequent depression and lower mental health scores. The combination of disproportionate shoulder pain, comorbid back pain and mental health conditions, and inferior preoperative expectations may affect not only the patient's preoperative state but also postoperative pain control and/or postoperative outcomes
Report on eighth WHO meeting on development of influenza vaccines that induce broadly protective and long-lasting immune responses: Chicago, USA, 23-24 August 2016
In August 2016, the World Health Organization (WHO) convened the "Eighth meeting on development of influenza vaccines that induce broadly protective and long-lasting immune responses" to discuss the regulatory requirements and pathway
Oseltamivir Prescribing in Pharmacy-Benefits Database, United States, 2004–20051
We reviewed information from a US pharmacy benefits manager database from 2004 through 2005 during periods with little influenza activity. We calculated rates of oseltamivir prescriptions to enrollees. Prescription rates increased significantly from 27.3/100,000 in 2004 to 134/100,000 in 2005 (p<0.05), which suggested that personal stockpiling of oseltamivir occurred
Effi cacy of a Russian-backbone live attenuated infl uenza vaccine among children in Senegal: a randomised, double-blind, placebo-controlled trial
Background Live attenuated infl uenza vaccines have been shown to signifi cantly reduce infl uenza in diverse
populations of children, but no effi cacy studies have been done in resource-poor tropical settings. In Senegal, we
assessed the effi cacy and safety of a live attenuated infl uenza vaccine based on Russian-derived master donor viruses
and licensed as a single dose.
Methods In this double-blind, placebo-controlled, parallel group, single-centre trial done near Niakhar, Senegal,
generally healthy children aged 2–5 years were randomly allocated (2:1) to receive a single intranasal dose of masked
trivalent live attenuated infl uenza vaccine or placebo. The allocation sequence was computer-generated by PATH with
block sizes of three. The manufacturer provided vaccine and placebo in coded vials to preserve blinding. Participants
were monitored through the predictable infl uenza season in Senegal for adverse events and signs and symptoms of
infl uenza using weekly home visits and surveillance in clinics. The primary outcome was symptomatic laboratoryconfi
rmed infl uenza caused by any strain and occurring from 15 days post-vaccination to the end of the study. The
primary analysis was per protocol. This study is registered with ClinicalTrials.gov, number NCT01854632.
Findings Between May 23, and July 1, 2013, 1761 children were randomly assigned, 1174 to receive live attenuated
infl uenza vaccine and 587 to receive placebo. The per-protocol set included 1173 vaccinees and 584 placebo recipients
followed up to Dec 20, 2013. Symptomatic infl uenza was laboratory-confi rmed in 210 (18%) of 1173 recipients of live
attenuated infl uenza vaccine and 105 (18%) of placebo recipients, giving a vaccine effi cacy of 0·0% (95% CI –26·4 to 20·9).
Adverse events were balanced between the study groups. Two girls who had received live attenuated infl uenza vaccine
died, one due to anasarca 12 days postvaccination and one due to malnutrition 70 days postvaccination.
Interpretation Live attenuated infl uenza vaccine was well tolerated in young children in Senegal, but did not provide
protection against infl uenza. Further study in such populations, which might experience extended periods of
infl uenza circulation, is warranted
Data and product needs for influenza immunization programs in low- and middle-income countries: Rationale and main conclusions of the WHO preferred product characteristics for next-generation influenza vaccines.
In 2017, WHO convened a working group of global experts to develop the Preferred Product Characteristics (PPC) for Next-Generation Influenza Vaccines. PPCs are intended to encourage innovation in vaccine development. They describe WHO preferences for parameters of vaccines, in particular their indications, target groups, implementation strategies, and clinical data needed for assessment of safety and efficacy. PPCs are shaped by the global unmet public health need in a priority disease area for which WHO encourages vaccine development. These preferences reflect WHO's mandate to promote the development of vaccines with high public health impact and suitability in Low- and Middle-Income Countries (LMIC). The target audience is all entities intending to develop or to achieve widespread adoption of a specific influenza vaccine product in these settings. The working group determined that existing influenza vaccines are not well suited for LMIC use. While many developed country manufactures and research funders prioritize influenza vaccine products for use in adults and the elderly, most LMICs do not have sufficiently strong health systems to deliver vaccines to these groups. Policy makers from LMICs are expected to place higher value on vaccines indicated for prevention of severe illness, however the clinical development of influenza vaccines focuses on demonstrating prevention of any influenza illness. Many influenza vaccine products do not meet WHO standards for programmatic suitability of vaccines, which introduces challenges when vaccines are used in low-resource settings. And finally, current vaccines do not integrate well with routine immunization programs in LMICs, given age of vaccine licensure, arbitrary expiration dates timed for temperate country markets, and the need for year-round immunization in countries with prolonged influenza seasonality. While all interested parties should refer to the full PPC document for details, in this article we highlight data needs for new influenza vaccines to better demonstrate the value proposition in LMICs
Effi cacy of a Russian-backbone live attenuated infl uenza vaccine among young children in Bangladesh: a randomised, double-blind, placebo-controlled trial
Background The rates of infl uenza illness and associated complications are high among children in Bangladesh.
We assessed the clinical effi cacy and safety of a Russian-backbone live attenuated infl uenza vaccine (LAIV) at two fi eld
sites in Bangladesh.
Methods Between Feb 27 and April 9, 2013, children aged 2–4 years in urban Kamalapur and rural Matlab, Bangladesh,
were randomly assigned in a 2:1 ratio, according to a computer-generated schedule, to receive one intranasal dose of
LAIV or placebo. After vaccination, we monitored children in weekly home visits until Dec 31, 2013, with study clinic
surveillance for infl uenza illness. The primary outcome was symptomatic, laboratory-confi rmed infl uenza illness due
to vaccine-matched strains. Analysis was per protocol. The trial is registered with ClinicalTrials.gov, number
NCT01797029.
Findings Of 1761 children enrolled, 1174 received LAIV and 587 received placebo. Laboratory-confi rmed infl uenza
illness due to vaccine-matched strains was seen in 93 (15·8%) children in the placebo group and 79 (6·7%) in the
LAIV group. Vaccine effi cacy of LAIV for vaccine-matched strains was 57·5% (95% CI 43·6–68·0). The vaccine was
well tolerated, and adverse events were balanced between the groups. The most frequent adverse events were
tachypnoea (n=86 in the LAIV group and n=54 in the placebo group), cough (n=73 and n=43), and runny nose (n=68
and n=39), most of which were mild.
Interpretation This single-dose Russian-backbone LAIV was safe and effi cacious at preventing symptomatic
laboratory-confi rmed infl uenza illness due to vaccine-matched strains. LAIV programmes might reduce the burden
of infl uenza illness in Bangladesh
- …